{"entity":{"id":"nct07553988","kind":"trial","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Abiraterone acetate, Prednisone in prostate cancer, run by R-Pharm International, LLC, active and no longer recruiting.","summary":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer is a phase 2 interventional study registered as NCT07553988 by R-Pharm International, LLC, with 120 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-05-14. Interventions recorded: RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mg, Abiraterone, Prednisolone. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07553988","url":"https://clinicaltrials.gov/study/NCT07553988"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","prednisone"],"companies":["r-pharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07553988","phase":"2","setting":"A Phase II, Open-label, Randomized, Comparative Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","sponsor":"R-Pharm International, LLC","enrolled":120,"outcomes":[]},"route":"/trials/nct07553988/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/"}]}}